New Drug Daraxonrasib Nearly Doubles Survival in Pancreatic Cancer Breakthrough
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Summary
Pancreatic cancer has long been one of the deadliest cancers, with over 97% of metastatic patients dying within five years. A new oral drug called daraxonrasib has achieved what scientists once considered impossible: neutralizing the KRAS protein mutation that drives more than 90% of pancreatic tumors. Instead of targeting KRAS directly, the drug binds to a helper molecule called cyclophilin A, which then shuts down KRAS signaling. In a Phase 3 clinical trial of 500 patients with advanced pancreatic cancer, daraxonrasib nearly doubled survival rates and reduced the risk of death by 60%. This marks a fundamental shift in how oncologists may approach one of medicine's most resistant cancers.
Detailed Summary
Pancreatic cancer has historically been a near-death sentence. For patients diagnosed with metastatic disease between 2015 and 2021, approximately 97% died within five years. The disease is notoriously difficult to detect early, often producing no symptoms until it has spread to other organs. This late-stage diagnosis, combined with a lack of precise treatment options, has made meaningful progress rare — until now.
The central problem has been a gene called KRAS, mutated in over 90% of pancreatic tumors. This mutation locks a critical cell-growth switch in the permanently "on" position, driving uncontrolled cancer cell proliferation. For decades, the KRAS protein was labeled "undruggable" because its unusually smooth surface offered no binding sites for conventional drugs. Chemotherapy remained the default — effective only as a blunt instrument that damages healthy tissue alongside cancerous cells.
Daraxonrasib, developed by Revolution Medicines, offers a fundamentally different mechanism. Rather than attacking KRAS directly, the oral drug binds to cyclophilin A, a protein that assists in folding other proteins into functional 3D shapes. This complex then attaches to active KRAS and disables its ability to drive tumor growth — an elegant molecular workaround to a longstanding biological obstacle.
Results from the Phase 3 clinical trial, presented on May 31, 2026, involved 500 patients with metastatic pancreatic cancer who had received prior treatment. The findings showed daraxonrasib nearly doubled survival and reduced the overall risk of death by 60% compared to existing standards of care. These numbers represent a dramatic departure from decades of stagnation in pancreatic cancer outcomes.
For health-conscious individuals and those tracking longevity medicine, this development signals broader progress in precision oncology — the shift from toxic, nonspecific chemotherapy toward targeted molecular therapies. While this drug addresses late-stage disease rather than prevention, the KRAS pathway insight may eventually inform earlier interventions and cancer-risk monitoring strategies.
Key Findings
- Daraxonrasib nearly doubled survival in metastatic pancreatic cancer patients in a 500-person Phase 3 trial.
- The drug reduced risk of death by 60% compared to prior standard-of-care treatments.
- KRAS mutation drives over 90% of pancreatic tumors and was previously considered completely undruggable.
- Daraxonrasib works indirectly via cyclophilin A, bypassing KRAS's smooth, pocket-free surface.
- This is an oral daily medication, offering a practical delivery advantage over infusion-based chemotherapy.
Methodology
This is a news report summarizing Phase 3 clinical trial results presented by Revolution Medicines on May 31, 2026, covering 500 patients with metastatic pancreatic cancer. The source article is authored by a gastrointestinal oncologist specializing in early-phase trials, lending clinical credibility. Full peer-reviewed publication of trial data has not yet been confirmed in the article text.
Study Limitations
The article is a research summary, not a peer-reviewed publication; full trial data has not yet been published in a journal. Survival benefit details such as median overall survival figures and side effect profiles are not fully disclosed in this report. Regulatory approval status of daraxonrasib is not confirmed, and results should be verified against the primary trial publication.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.